| Unsubscribe |
Stop Reading About Winners.
Start Finding Them.
The internet is full of stories about stocks that already exploded..
We focus on the ones that haven't... yet.
Get instant alerts delivered directly to your phone and inbox.
(Clicking the link will sign you up for Huge Alerts' newsletter, cancel any time)
Opportunity doesn't wait.
Aehr Test Systems Soars Again on Latest Orders, Jefferies Eyes Big-Time Upside Ahead
Reported by Leo Miller. Published: 8/24/2026.
Key Points
- Aehr Test Systems has become one of 2026’s standout AI-linked stocks after a dramatic run in its share price.
- Recent orders for the company’s FOX-XP systems are putting its exposure to AI processors and silicon photonics in focus.
- With ambitious fiscal 2027 guidance in place, investors are watching whether new orders can translate into the revenue needed to support Aehr Test Systems’ valuation.
- Special Report: The company SpaceX cannot operate without
Investing in the artificial intelligence theme has been nothing short of a wild ride in 2026, especially when it comes to lesser-known stocks. Few stocks provide a better example of this dynamic than semiconductor testing equipment company Aehr Test Systems (NASDAQ: AEHR).
Throughout the year, Aehr's market capitalization has increased from less than $700 million to well over $3 billion. This has resulted in a year-to-date (YTD) return of more than 400%, making Aehr one of the best-performing stocks of 2026.
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (Ad)
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor.
This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.
Click here to learn this company's name for free todayAehr had already delivered an impressive performance through July, gaining nearly 300% YTD. However, the stock moved into a different stratosphere in August, with shares up more than 30% during the month. This comes despite AEHR dropping 25% from its August high, demonstrating the immense volatility surrounding the stock.
Notably, repeated orders for Aehr's AI chip testing systems, rather than hype, are driving its ascendance, with two recent orders pushing shares to new heights.
Aehr Secures Millions in Orders for FOX-XP
Aehr has highlighted two new orders, one small and one large, but both are notable. First, the company says it has received an order from its lead silicon photonics customer for a FOX-XP system. FOX-XP is Aehr's wafer-level burn-in (WLBI) machine, which subjects semiconductor wafers to intense conditions to test for defects. The order is notable because it comes from a silicon photonics customer, a high-growth area within the AI semiconductor industry. Experts expect silicon photonics to become increasingly important within AI networking because of its superior bandwidth compared with copper-based networking.
Gaining silicon photonics customers signals Aehr's ability to generate demand from this high-growth market. Furthermore, this is a repeat order, showing that the customer has found Aehr's machines useful and is supporting production with additional orders. Still, the order is small, consisting of just one FOX-XP system.
Aehr's second order announcement is far more significant. Aehr notes that it has also received a follow-on order from its lead wafer-level AI processor customer, which makes AI training and inference chips. The order, valued at $22 million, includes multiple FOX-XP machines and various types of ancillary equipment. At first glance, a $22 million order may sound relatively small, but Aehr is a relatively small company.
Investors should note that several months ago, Aehr said it had received a $41 million commitment, which marked a record order for the company. Bringing in a new order that is slightly more than half the size of its largest-ever order is therefore very significant. This is especially true when it comes to Aehr's ability to meet its guidance.
Aehr's Recent Orders Support Lofty Guidance Goals
Aehr released blockbuster guidance during its last earnings report, estimating that it would generate $130 million to $150 million in sales during its fiscal year 2027 (FY2027). Note that Aehr's fiscal reporting period is several quarters ahead of the calendar year, with FY2027 having begun in June. Achieving these figures would represent explosive growth of approximately 160% to 200% year over year compared with its fiscal year 2026 sales of $50 million.
At the time of its last report, Aehr's effective backlog of $100.6 million covered approximately 66% to 77% of its revenue guidance. With the new $22 million order expected to ship within the next six months, it should contribute directly to Aehr's FY2027 revenue target. All else being equal, the order would increase Aehr's effective backlog to $122.6 million.
Thus, the company's effective backlog would account for approximately 82% to 94% of its revenue guidance, substantially increasing the likelihood that it meets its target. Notably, to meet the midpoint of its guidance, or $140 million, Aehr only needs to generate and deliver additional orders worth approximately $18.4 million.
With the company generating at least $22 million in orders during the first three months of FY2027, Aehr appears to be on track to meet its goal. Aehr says its AI processor customers' “current production plans contemplate capacity beyond this order,” suggesting they could submit additional orders going forward.
Aehr Gains Sky-High Price Target as Valuation Bakes in Big-Time Growth
Aehr now trades at a forward price-to-sales (P/S) ratio of approximately 25x. This highly elevated figure demonstrates the substantial amount of growth the market is pricing into the stock. However, it is significantly below Aehr's peak forward P/S ratio of nearly 45x.
Aehr carries a Buy rating with a price target of $136.67 and has recently received a lofty $175 price target from Jefferies. Jefferies recently initiated coverage of the company, and its target implies significant upside. However, if Aehr is to reach this target, the stock is unlikely to move in a straight line. Aehr can see single-day gains and drops of 20% or more, further highlighting the stock's high-risk nature.
Investors interested in this name should monitor Aehr's ability to convert its large backlog into actual revenue, which will require strong production execution. Additionally, it will be important to see whether Aehr expands its customer base into new areas of AI chips. Order announcements involving memory chip or central processing unit (CPU) customers would be particularly notable, as these are also high-growth AI infrastructure segments.
Amid Legal Risks, This Company Is Still Rated a Buy
Reported by Peter Frank. Published: 8/19/2026.
Key Points
- PACS Group's stock has rebounded strongly after collapsing more than 80% amid a short seller's Medicare billing allegations and a federal investigation in 2024.
- Second-quarter results showed revenue up 9.1% and adjusted EPS beating estimates, prompting management to raise full-year revenue and adjusted EBITDA guidance.
- Analysts rate PACS a consensus Buy with meaningful upside, but ongoing DOJ and SEC investigations and an active securities fraud lawsuit remain unresolved risks.
- Special Report: The company SpaceX cannot operate without
When investors look for stocks riding the aging of America, they might consider hospital chains, pharmacy benefit managers or dividend-paying healthcare REITs.
What few might expect is PACS Group (NYSE: PACS), a skilled nursing operator whose stock fell more than 80% in a year after a short seller accused it of gaming Medicare. The company delayed financial reports, a federal investigation began and its chief financial officer was replaced.
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (Ad)
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor.
This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.
Click here to learn this company's name for free todayNow, less than two years later, analysts rate the company a Buy. With the stock having fully rebounded, investors might want to consider whether PACS is one of the market's more improbable comebacks with room to run or whether legal risks are still clouding its future.
A Stunning Rise Followed by a Collapse
PACS went public in April 2024 in a $450 million IPO at $21 per share, valuing the company at more than $3 billion. Within seven months, its stock had more than doubled.
That’s when short seller Hindenburg Research accused the company of fueling its growth with aggressive Medicare billing. The stock soon cratered amid federal investigations, delayed earnings and an accounting restatement.
Shares eventually bottomed at $7.50 in 2025, soon after the company’s chief financial officer resigned when it was found that he had accepted gifts from business partners.
The Numbers Behind the Rally
Since then, however, the company’s performance has maintained its momentum. The case for a comeback grew even stronger in August, when PACS reported its second-quarter results.
The company said revenue rose 9.1% year-over-year to $1.43 billion, beating Wall Street's $1.41 billion expectation. Net income jumped 49.8% to $76.3 million, while diluted earnings per share (EPS) climbed 51.6% to 47 cents. Adjusted EPS of 63 cents topped analysts’ consensus by 9 cents.
The underlying numbers were equally strong. The adjusted earnings before interest, taxes, depreciation, amortization and rent (EBITDAR) margin expanded 150 basis points, from 10.2% to 11.7%. Same-store skilled nursing revenue grew 5.8%, and the company said it treated a richer mix of higher-acuity patients.
Management liked what it saw enough to raise full-year guidance to between $5.75 billion and $5.85 billion in revenue and between $640 million and $660 million in adjusted EBITDA. Both ranges increased from prior targets.
That builds on a 2025 in which revenue grew 29.3% to $5.3 billion, while net income reached $191.5 million.
Growth Accelerates in a Fragmented Market
PACS's results show the potential of operating in a fragmented industry that continues to face more demand than supply.
Already one of the largest skilled nursing platforms in the country, PACS subsidiaries operate 344 post-acute care facilities across 17 states, serving more than 33,400 patients daily. Further, PACS agreed in June to acquire 34 skilled nursing facilities with 3,633 beds from Eduro Healthcare across six Western states.
With a healthy balance sheet, that growth can continue. The company reported more than $700 million of available liquidity, including $164.5 million in cash, at quarter-end.
Analysts See More Upside Ahead
Wall Street has taken notice. Seven analysts carry a consensus Buy rating on the stock: one Strong Buy, five Buys and one Hold.
The company carries an average 12-month price target of $56, compared with a recent price of about $44, implying roughly 25% upside. UBS, RBC, Oppenheimer and Truist all raised their targets after the earnings report, while Zacks Research lifted its recommendation from Hold to Strong Buy.
Legal and Regulatory Risks Remain
The most obvious reason for caution, however, is the one the earnings report cannot fix. The Department of Justice has multiple ongoing investigations into PACS, examining potential False Claims Act violations tied to Medicare billing, Anti-Kickback Statute referral practices, pandemic-era waiver claims and allegedly false statements to the government.
The company also disclosed that it is under investigation by the Securities and Exchange Commission in connection with its accounting, financial reporting and disclosures. PACS, for its part, said it cannot estimate the timing or financial impact.
In addition, a securities fraud class action covering shareholders who bought stock between April and December 2024 remains active, and another law firm announced a fresh shareholder investigation into the board in July.
Insider activity has also been notable. Corporate insiders own roughly 70% of the shares, which could be read as a vote of confidence. However, they also sold more than $39 million in stock over the past 12 months.
A Riskier Way Into a Steady Trend
For all these reasons, PACS might be best understood as a leveraged bet on a demographic trend that is also broadly lifting other skilled nursing names, such as The Ensign Group (NASDAQ: ENSG), The Pennant Group (NASDAQ: PNTG) and National HealthCare (NYSEAMERICAN: NHC).
There’s no doubt that the aging-population tailwind is real and durable across the industry. Whether PACS can continue compounding, however, depends largely on outcomes beyond its earnings power.
With multiple investigations still open and no timeline for their closure, investors will have to wait for those outcomes.
This email content is a sponsored message provided by Trading Wire, a third-party advertiser of The Early Bird and MarketBeat.
If you need assistance with your newsletter, please contact MarketBeat's South Dakota based support team at contact@marketbeat.com.
If you no longer wish to receive email from The Early Bird, you can unsubscribe.
© 2006-2026 MarketBeat Media, LLC. All rights protected.
345 North Reid Place, Sixth Floor, Sioux Falls, South Dakota 57103. U.S.A..
No comments:
Post a Comment